Actinium Pharma Presents Survival Data From Extended Follow-Up From Actimab-A + CLAG-M Trial And Preclinical Data Supporting Program Expansion With FLT3 Inhibitor Combinations At SOHO
- Extended follow-up in the Actimab-A + CLAG-M trial showed median overall survival in patients proceeding to bone marrow transplant of 24 months in all patients and 30 months in patients who received prior